Association between response to neoadjuvant chemotherapy and survival outcome after radical surgery in patients with yielding pathological T2≤ and/or N+ urothelial carcinoma
Background and Aim: In early 2022, the use of adjuvant nivolumab for patients with high-risk muscle-invasive urothelial carcinoma was approved in Japan, European countries, and USA based on the positive results of CheckMate 274 trial, which included participants who received neoadjuvant chemotherapy (NAC). Subgroup analyses of CheckMate 274 trial does not report response to neoadjuvant chemotherapy and benefit from adjuvant nivolumab. Herein, we investigated the association between response to NAC and survival outcomes after radical surgery in patients with residual muscle-invasive urothelial carcinoma and/or lymph node disease.
Methods: This multicenter retrospective study included a total of 95 NAC-treated patients with yielding pathological (yp) T2≤ and/or ypN+ urothelial carcinoma on radical surgery specimens. Based on the comparison of clinical T and N category with yp T and N category, the patients were categorized into three groups: down-staged ypT2≤ (n=14), no-changed ypT2≤ (n=39), and up-staged ypT2≤ groups (n=42).
Results: There was no significant difference in extra-urinary tract recurrence-free survival, cancer-specific survival, and overall survival after the radical surgery among three groups. Subgroup analysis of a bladder cancer cohort showed a marginal association between better response and longer cancer-specific survival (P=0.073).
Conclusion: Our finding suggested that adjuvant nivolumab should be considered for all the patients with pathological ypT2≤ or ypN+ urothelial carcinoma regardless of response to NAC. Further research is mandatory in finding predictive factors that serve in decision-making for NAC-treated patients who are likely to benefit from adjuvant nivolumab.
Relevance for patients: To develop a decision-making tool for adjuvant nivolumab, we investigated the association between response to neoadjuvant chemotherapy and survival after radical surgery. Further research is mandatory in finding predictive factors that serve in decision-making for NAC-treated patients who are likely to benefit from adjuvant nivolumab.
[1] Miyake M, Iida K, Nishimura N, Inoue T, Matsumoto H, Matsuyama H, et al. Site-specific risk stratification models for postoperative recurrence and survival prediction in patients with upper tract urothelial carcinoma undergoing radical nephroureterectomy: Better stratification for adjuvant therapy. Eur Urol Open Sci 2022;41:95-104.
[2] Novara G, De Marco V, Gottardo F, Dalpiaz O, Bouygues V, Galfano A, et al. Independent predictors of cancer-specific survival in transitional cell carcinoma of the upper urinary tract: multi-institutional dataset from 3 European centers. Cancer 2007;110:1715-22.
[3] Li CC, Chang TH, Wu WJ, Ke HL, Huang SP, Tsai PC, et al. Significant predictive factors for prognosis of primary upper urinary tract cancer after radical nephroureterectomy in Taiwanese patients. Eur Urol 2008;54:1127-34.
[4] Margulis V, Shariat SF, Matin SF, Kamat AM, Zigeuner R, Kikuchi E, et al. Outcomes of radical nephroureterectomy: A series from the upper tract urothelial carcinoma collaboration. Cancer 2009;115:1224-33.
[5] Birtle A, Johnson M, Chester J, Jones R, Dolling D, Bryan RT, et al. Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): Aphase 3, open-label, randomised controlled trial. Lancet 2020;395:1268-77.
[6] Oswald D, Pallauf M, Deininger S, Törzsök P, Sieberer M, EibenC. Neoadjuvant chemotherapy before nephroureterectomy in high-risk upper tract urothelial cancer: A Systematic review and meta-analysis. Cancers (Basel) 2022;14:4841.
[7] Witjes JA, Bruins HM, Carrión A, Cathomas R, Compérat E, Efstathiou JA, et al. European association of urology guidelines on muscle-invasive and metastatic bladder cancer: Summary of the 2023 guidelines. Eur Urol 2023;S0302-2838(23)03073-7.
[8] Flaig TW, Spiess PE, Abern M, Agarwal N, BangsR, Boorjian SA, et al. NCCN Guidelines® insights: Bladder cancer, version 2.2022. J Natl Compr Canc Netw 2022;20:866-78.
[9] Matsumoto H, Shiraishi K, Azuma H, Inoue K, Uemura H, Eto M, et al. Clinical practice guidelines for bladder cancer 2019 update by the Japanese urological association: Summary of the revision. Int J Urol 2020;27:702-9.
[10] Yin M, Joshi M, Meijer RP, Glantz M, Holder S, Harvey HA, et al. Neoadjuvant chemotherapy for muscleinvasive bladder cancer: A systematic review and two-step meta-analysis. Oncologist 2016;21:708-15.
[11] Iyer G, Tully CM, Zabor EC, Bochner BH, Dalbagni G, Herr HW, et al. Neoadjuvant gemcitabine-cisplatin plus radical cystectomy-pelvic lymph node dissection for muscle-invasive bladder cancer: A 12-year experience. Clin Genitourin Cancer 2020;18:387-94.
[12] Kuwada M, Miyake M, Gotoh D, Tatsumi Y, Nakai Y, Anai S, et al. Pretreatment platelet-to-lymphocyte ratio as biomarker for neoadjuvant chemotherapy prior to radical cystectomy in muscle-invasive bladder cancer. J Nara Med Assoc 2017;68:29-41.
[13] Miura Y, Hatakeyama S, Tanaka T, Fujita N, Horiguchi H, Okuyama Y, et al. Prognostic impact of eligibility for adjuvant immunotherapy in locally advanced urothelial cancer. BJUI Compass 2022;3:146-53.
[14] Bajorin DF, Witjes JA, Gschwend JE, Schenker M, Valderrama BP, Tomita Y, et al. Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma. N Engl J Med 2021;384:2102-14.
[15] Yan C, Huang M, Swetlik C, Toljan K, MahadeenAZ, Bena J, et al. Predictors for the development of neurological immunerelated adverse events of immune checkpoint inhibitors and impact on mortality. Eur J Neurol 2023;30:3221-7.
[16] Caiati C, Jirillo E. Immune checkpoint inhibitor-mediated cardiovascular disease: the dark side of the monoclonal anti-body therapy against cancer. Endocr Metab Immune Disord Drug Targets 2023;23:1365-7.
[17] Defoe M, Bermas BL. Rheumatologic immune checkpoint inhibitor-related adverse events. Curr Opin Rheumatol 2023;35:141-8.
[18] Iwamoto Y, Kimura T, Iwamoto H, Sanada J, Fushimi Y, Katakura Y, et al. Incidence of endocrine-related immune-related adverse events in Japanese subjects with various types of cancer. Front Endocrinol (Lausanne) 2023;14:1079074.
[19] Galsky MD, Witjes AA, Gschwend JE, Schenker M, Valderrama BP, Bamias A, et al. Extended followup results from the CheckMate 274 trial. J Clin Oncol 2023;41 Suppl 6:LBA443.
[20] Vellinga A, Cormican M, Hanahoe B, Bennett K, Murphy AW. Opt-out as an acceptable method of obtaining consent in medical research: A short report. BMC Med Res Methodol 2011;11:40.
[21] Mammen S, Krishna S, Quon M, Shabana WM, Hakim SW, Flood TA, et al. Diagnostic accuracy of qualitative and quantitative computed tomography analysis for diagnosis of pathological grade and stage in upper tract urothelial cell carcinoma. J Comput Assist Tomogr 2018;42:204-10.
[22] Honda Y, Nakamura Y, Teishima J, Goto K, Higaki T, Narita K, et al. Clinical staging of upper urinary tract urothelial carcinoma for T staging: Review and pictorial essay. Int J Urol 2019;26:1024-32.
[23] Gschwend JE, Heck MM, Lehmann J, Rübben H, Albers P, Wolff JM, et al. Extended versus limited lymph node dissection in bladder cancer patients undergoing radical cystectomy: Survival results from a prospective, randomized trial. Eur Urol 2019;75:604-11.
[24] Miyake M, Tatsumi Y, Fujimoto K, Nagao K, Sakano S, Matsuyama H, et al. Changes in oncological outcomes after radical nephroureterectomy in patients with upper urinary tract urothelial carcinoma treated in the last two decades: a retrospective analysis based on a multicenter collaborative study. Jpn J Clin Oncol 2016;46:1148-55.
[25] Kondo T, Hashimoto Y, Kobayashi H, Iizuka J, NakazawaH, Ito F, et al. Template-based lymphadenectomy in urothelial carcinoma of the upper urinary tract: Impact on patient survival. Int J Urol 2010;17:848-54.
[26] Grivas P, Agarwal N, Pal S, Kalebasty AR, Sridhar SS, Smith J, et al. Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practice. Cancer Treat Rev 2021;97:102187.
[27] Miyake M, Shimizu T, Nishimura N, Kiba K, Maesaka F, Oda Y, et al. response to pembrolizumab after dose-reduced cisplatin plus gemcitabine chemotherapy is inferior to that after carboplatin plus gemcitabine chemotherapy in cisplatin-unfit patients with advanced Urothelial Carcinoma. Clin Genitourin Cancer 2022;20:196.e1-9.
[28] Kato M, Kobayashi T, Matsui Y, Ito K, Hikami K, Yamada T, et al. Impact of the objective response to and number of cycles of platinum-based first-line chemotherapy for metastatic urothelial carcinoma on overall survival of patients treated with pembrolizumab. Int J Urol 2021;28:1261-7.
[29] Ferro M, Chiujdea S, Vartolomei MD, Bove P, Porreca A, Busetto GM, et al. Advanced Age Impacts Survival after Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma. Clin Genitourin Cancer 2023:S1558-7673(23)00184-2.
[30] Ferro M, Crocetto F, Tataru S, Barone B, Dolce P, Lucarelli G, et al. Predictors of efficacy of immune checkpoint inhibitors in patients with advanced urothelial carcinoma: A systematic review and meta-analysis. Clin Genitourin Cancer 2023;21:574-83.
[31] Mori K, Katayama S, Laukhtina E, Schuettfort VM, Pradere B, Quhal F, et al. Discordance between clinical and pathological staging and grading in upper tract urothelial carcinoma. Clin Genitourin Cancer 2022;20:95.e1-95.e6.